The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.
1 Primary · 3 Secondary · Reporting Duration: From Day 1 up to Week 100
Experimental Treatment
850 Total Participants · 1 Treatment Group
Primary Treatment: VX-121/TEZ/D-IVA · No Placebo Group · Phase 3
Age Any Age · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: